Articles

Poll

Podcasts

Slideshows

Videos

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective. 

Endocrinology Month in Review: May 2023

The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.

One-Third of US Adults with Type 2 Diabetes Show Evidence of Subclinical CVD 

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

Exploring the Impact of the Sotagliflozin Approval, with Deepak Bhatt, MD, MPH

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

FDA Approves Sotagliflozin for Treatment of Heart Failure

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

Diabetes Dialogue: What to Know about the iLet Bionic Pancreas

An analysis of data from the ARIC study is offering new insight into the impact of age at diabetes onset on the risk of developing dementia later in life. 

Earlier Age at Diabetes Onset Confers Greater Risk of Dementia Later in Life

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

Phase 2b Trial Suggests Efficacy of Oral Danuglipron for Glycemic Control in T2D

In this episode, hosts sit down for an in-depth discussion of the 11 person-centered algorithms for clinical decision-making featured in the AACE's 2023 Comprehensive Type 2 Diabetes Management Algorithm. 

Diabetes Dialogue: Breaking Down AACE's New Type 2 Diabetes Management Algorithms

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.

GLP-1 for NASH? A Hepatologist's Perspective on Current Data

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy. 